Systematic review shows GLP-1RAs and SGLT2is improve outcomes in type 1 diabetes, balancing safety concerns.
Adjunctive GLP-1RAs and SGLT2is provide modest clinical improvements in adults with type 1 diabetes. These benefits must be balanced against class-specific safety concerns, especially the increased risk of DKA with SGLT2-based therapies. Larger, long-term trials are needed to define their optimal use in routine care.
No takes yet. Share an insight, caveat, or question.
Abdel‐Rahman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: